Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Authors
Keywords
Overall Survival, Tumor Microenvironment, Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Akaike Information Criterion
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 23, Issue 8, Pages 2610-2617
Publisher
Springer Nature
Online
2016-03-24
DOI
10.1245/s10434-016-5101-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
- (2014) John Bridgewater et al. JOURNAL OF HEPATOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Risk factors for cholangiocarcinoma
- (2011) Gia L. Tyson et al. HEPATOLOGY
- Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
- (2010) Horlad Hasita et al. CANCER SCIENCE
- Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion
- (2009) Yufu Ye et al. JOURNAL OF SURGICAL ONCOLOGY
- Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature
- (2008) Murad Aljiffry et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started